
EGFR/MET双特异性抗体埃万妥单抗实现了EGFR突变晚期NSCLC广泛覆盖黄金炒股配资网。
*以下内容仅供医疗卫生专业人士浏览。

审批编码:CP-555414批准分发日期:2025/11/28有效期:2026/11/28
参考文献:
[1]Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.
[2]Lu S, Byoung CC, Jong-Seok L, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.
[3]Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805-816.
[4]Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. 2025 ELCC. 4O.
[5]中国医药教育协会肺癌医学教育专业委员会,北京医学奖励基金会肺癌医学青年专家委员会脑转移协作组,支修益,et al.中国驱动基因阳性脑转移临床诊疗指南(2025版)[J].中国肺癌杂志,2025,28(1):1-21.
[6]Shirish MG, Byoung CC, Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.
[7]Zhou CC, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[8]Caicun Zhou , et al. Amivantamab Plus Chemotherapy vs Chemotherapy as a First-line Treatment Among Asian Patients With EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): PAPILLON Subgroup Analysis. 2023 ESMO Asia. 513 MO.
[9]Passaro A, Wang J, Wang Y, et, al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.
[10]Shih J, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.
[11]Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056.
[12]Zhou Q, Zhao H, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024;53:101260.
[13]Brazel D, Nagasaka M. The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023 Oct 25;24(1):256.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
瑞和网官网提示:文章来自网络,不代表本站观点。